The tool caramel for treatment of diseases of bacterial origin


The invention relates to medicine, in particular to pharmacology, namely the creation of new drugs based on peptides for the treatment and prevention of diseases of bacterial origin, caused by Staphylococcus aureus, Escherichia coli, pneumococcus and other Proposed means includes a linear Hexapeptide structural formula Leu-Val-Cys-Tyr-Pro-Gln and glycine in a ratio of ingredients is 1:1 to 1:2, at a dose of 0.007 mg/kg of weight of the person. The invention allows to create a new medication without side effects and to develop a method for its use for the treatment and prevention of diseases caused by bacterial nature. 7 table.

The invention relates to medicine, in particular for anti-infective pharmacology, namely the creation of new medicines, which have antibacterially action, on the basis of peptides and intended for the treatment and prevention of infectious diseases of bacterial origin, caused by Staphylococcus aureus, Escherichia coli, pneumococcus and other

Known use in antibacterial therapy of different antibiotics. Among them one should mention the drugs group is key aminoglycosides, macrolides and azalides, etc. However, all known antibiotics have a whole range of side effects on the body and, in addition, long-term use, the development of resistance of microorganisms.

In addition to antibiotics, widely in medical practice for the treatment of infectious diseases use of sulfa drugs, which are often used in combination with antibiotics. From side effects of sulfa drugs should be called allergic reactions, nausea, vomiting, dermatitis, neuropathy, disorders of the Central, very often impaired renal function. Introduction in an organism of the patient described drugs in therapeutic doses, can lead to severe side effects, particularly immunodeficiencies. Therefore, it is much preferable to use as antibacterial agents of low molecular weight compounds, especially peptide. They are effective in small doses, does not cause harmful effects.

The prior art connection peptide with antibacterial effect, and tools based on them [1, 2, 3].

The present invention is the creation of a new domestic preparation on the basis of peptide devoid specified is odd, that the proposed means of having high antibacterial activity, containing linear Hexapeptide structural formula: Leu-Val-Cys-Tyr-Pro-GIn and glycine as a filler in the ratio of ingredients is 1:1 to 1:2 and named Seramil.

The Hexapeptide was isolated from culture supernatant of bone marrow cells pigs, sekvenirovan and then synthesized [4].

Stated the vehicle was prepared as follows: linear Hexapeptide mixed with glycine in the stated weight ratios, dissolved in distilled water, poured into ampoules or vials so that each vial contained 0.5 mg Hexapeptide, lyophilized solution, and then sealed ampoules or sterile sealed vials. The tool is a light white powder, soluble in water, physiological solution.

The technical result to be obtained by the use of the invention is the development of new drugs and the development of methods of their use for the treatment and prevention of infectious diseases caused by bacterial nature.

The invention is illustrated by the following examples.

Example 1. The stated means includes ingredients when following their zootoxin and following their ratio of mg: Linear Hexapeptide Leu-Val-Cys-Tyr-Pro-Gln - 1.0 Glycine - 1.0 To Any change in the qualitative or quantitative parameters of the proposed framework does not provide the claimed technical result.

The claimed product is used for injection at a dose of 0.007 mg/kg or 0.5 mg/person as an antibacterial agent. Specific (antibacterial) activity was studied on animal testing of the drug conducted on volunteers with chronic pneumonia.

Impact funds Seramil on the colonization of the internal organs of mice infected with pathogenic microorganisms.

It is known that the intensity of development and the outcome of infection is largely dependent on the residence time of pathogens in the body - terms of their persistence and colonization of internal organs. In a series of experiments investigated the influence of the stated means Seramil on the degree of contamination of the internal organs of infected animals in time. The experiments were conducted on female mice-hybrids (CBAC57Bl/6)F1weighing 18-22 g (20 experimental and 20 control). The day before the intraperitoneal infection of mice to sublethal dose of bacteria cultures they were injected intraperitoneally Seramil at a dose of 0.01 μg/mouse. In experiments were used culture is rangapani, mice - sepsis; - P. Aeruginosa, strain 1677 (Escherichia coli is the causative agent of wound infections; S. aureus, strain 57 (Staphylococcus aureus is the causative agent of purulent and toxic infections.

Control group mice (without prior introduction of Sarmila) were infected simultaneously with experienced. Then at different times (depending on the type of pathogen) were opening five experimental and five control mice with subsequent seeding of the pathogen from the blood, liver, spleen, mesenteric lymph nodes and different parts of the small and large intestine. After 18 hours incubation at 37oFrom the resulting culture were identified by diagnostic sera and calculated the index of contamination (the ratio of the number of positive samples in all investigated organs for all delivered to the samples). The closer the index of contamination to the unit, the greater the contamination of the body of the mouse.

In the study of Kl. pneumoniae strain K-16, the mice were infected intraperitoneally at a dose of 5106microbial cells/mouse. The day before infection were introduced Seramil at a dose of 0.01 μg/mouse. The index of contamination of animals was determined at 1, 2, 3, 6, 7 and 8 days after infection. Table 1 presents data on the effect of MP-3 clearance Klebsiella is Noah and control groups during the first three days did not differ from each other, however, on the fourth day, there was a sharp decline in the number of bacteria in mice of the experimental group compared with the control. 7-8 day has been full clearance culture of Bobadilla pneumonia in experience, whereas in the control of internal organs mice were inseminated by these organisms. Antibodies in the serum of experimental and control groups of mice were not detected.

The index definition contamination after infection of mice P. aeruginosa was carried out on 1, 2, 3 and 5 days after infection, and antibody titers were determined on 7 and 14 day. Dynamics of the index of contamination with animal infections by Escherichia coli are presented in table 2.

The data presented show that with the introduction of funds Pseudomonas aeruginosa derived from mice already on the second day after infection, whereas in the control of bacteria persist until the 5th day. The process is accompanied by an increase in antibody titer in the serum of both groups equally, despite the absence of the pathogen in the experimental group at the end of the observation period (table 3).

Infection of mice with S. aureus strain 57 index of contamination, as well as antibody titer in the serum was performed at 1, 2, 3 and 6 days. Dinamic data shows, that Staphylococcus aureus in mice that received vehicle Seramil, is present in smaller amount in comparison with the control. On the 6th day experimental mice were completely free of the pathogen, while in the control was still a minor infection. Differences in antibody titers were insignificant (table 5).

Impact funds Seramil on the colonization of the internal organs of mice infected with different pathogenic microorganisms was evaluated in a series of experiments upon its introduction in already infected organism. Experimental and control groups of mice were infected intraperitoneally sublethal (pre-titrated) dose of bacteria cultures. In experiments were used to culture the causative agents of the following bacterial infections:
- Kl. Pneumoniae, strain K-16;
- P. Aeruginosa, strain 1677.

2, 3 and day 4 after infection, the mice of the experimental group was injected subcutaneously substance of Sarmila at a dose of 0.01 μg/mouse. Then at different times made the opening five mice experimental and control groups with subsequent seeding of the blood, liver, spleen, mesenteric lymph nodes and different parts of the small and large intestine. After 18 hours incubation at 37oWith dedicated to the Ah to study the effects of Sarmila on the colonization of the internal organs of mice, infected Kl. Pneumoniae, the observations were carried out for 1 to 9 days. Seramil was injected three times at 2, 3 and 4 days after infection. The results of these studies are presented in table 6.

As can be seen from the data presented, the introduction Ceramic during infection of mice with Klebsiella pneumonia significantly reduces the colonization of organs of mice on day 7 there is a complete disappearance of the pathogen from the body, while the control mice pathogen is detected and on the 9th day from the moment of infection.

When studying the effect of the declared funds Seramil on the colonization of the internal organs of mice infected with P. Aeruginosa, the observations were carried out at 1-7 days after infection. The results of the experiments are presented in table 7.

As can be seen from the presented data, after double injection substance of Sarmila the colonization of the internal organs of mice dramatically falls to 5 days there is a complete cleansing of the organs of mice against the pathogen in the experimental group, while of the organs of control mice pathogen were inoculated to 7 days.

The data on the clearance of the organs of infected animals from pathogens of various bacterial infections allow to conclude that Caramel significantly SN the sludge, proposed for use as antimicrobial drugs. The program Toxicological research involved the study of the toxicity of the substance of tools in a single laboratory animals, the study of the toxicity of the substance of tools and finished dosage forms in chronic experiments on rats and dogs. In addition, a study was made irritant action of finished dosage form tools, research potential mutagenic, embryotoxic, teratogenic and allergenic properties, tools, and investigated its influence on the reproductive function of animals.

It is shown that the substance of sarmila is low-toxic substance; not set the death of BALB/C mice and WISTAR rats with a single intraperitoneal and subcutaneous possible for technical reasons doses (the limit of solubility of the drug) 925-950 mg/kg the dose more than 130 000 times the daily therapeutic dose (0.5 mg/person or 0.007 mg/kg).

Studied at subcutaneous doses of 0.14 and 0.35 mg/kg in 3-month chronic experiment on rats substance and a 3-month chronic experiment on sobaku dose of 0.14 mg/kg, in excess of 20 and 50 times the daily therapeutic dose for humans, well tolerated by the animals and do not cause toxic lesions. The finished dosage form of sarmila does not have irritant properties.

In the tested doses and concentrations Seramil does not show mutagenicity in the Ames test, does not cause chromosomal aberrations in bone marrow cells of mammals, dominant lethal mutations in germ cells of mice, has no DNA-damaging effect in the SOS chromotest, indicating the absence of the drug have the potential carcinogenic hazard.

In the tested dose of 0.14 mg/kg Seramil does not show embryotoxic and teratogenic properties, and does not affect the reproductive function of animals.

In the range of tested doses and schemes sensitization Seramil has no properties.

Antibacterial action funds was studied on a group of volunteers with chronic pneumonia. The patients ' age from 35 to 60 years, the number of patients in the group of 10 people. Before the study, all patients were treated with conventional drugs: antibiotics, sulfonamides according to the standard scheme, however, signs hronicheskogo during exercise, periodic fever, pain in the chest. Radiographically, all 10 people identified pockets of pneumonic infiltration, inflammation and deformation of the bronchi, increased ESR, increased C-reactive protein. The treatment claimed by the tool: 5 injections of Sarmila 0.5 mg/person a day, if necessary, a second course in 2-3 weeks. Upon completion of the course of treatment, the total state of the patient improved significantly: " there was a cough, body temperature remained within normal limits, stopped torturing pain in the chest. Radiographically in all patients decreased foci of infiltration, 6 people foci of infiltration is not found, the inflammation of the bronchi mentioned by only 1 person, erythrocyte sedimentation rate and C-reactive protein within the physiological norm.

Thus, on the basis of the conducted research it can be concluded that the proposed tool has a high antibacterial activity, non-toxic, does not show mutagenicity, has no allergenic and irritant properties, does not show embryotoxic and teratogenic properties.

1. EN 2183643 C1, 20.06.2002.

2. EN 2141483 C1, 20.11.1999.

3. EP 0979831,16.02.2000 - the prototype.

4. R. C. Smith and others the treatment of diseases of bacterial origin, containing peptide, characterized in that it comprises a linear Hexapeptide structural formula Leu - Val - Cys - Tyr - Pro - Gln and glycine in a ratio of components 1: 1 to 1: 2, and the dose means is 0.007 mg/kg of weight of the person.


Same patents:

The invention relates to peptides of General formula a-B-C-D-Pro-Gly-Pro-X, where A - O-Met(O), -Met, -Thr, -Ala, -Lys-Gly, -Glu, -Arg, -His, -Phe -,- Tyr, -Trp, B - O, -Glu, -Lys, -Tyr, -Gly, -Arg-Val-Pro; - O, -His, -Pro-Asp-Gly, -Arg, -Tyr, -Val-Phe; D - O-Phe, -His, -Arg, -Lys, -Ala, -Tyr, -Thr, -Pro-Ile; X - O-Ilе, highly neurotropic activity (refers to the lack of amino acids), provided that excluded peptides: Glu-His-Phe-Pro-Gly-Pro, Thr-Lys-Pro-Arg-Pro-Gly-Pro, Tyr-Pro-Phe-Pro-Gly-Pro-Ile and Met-Glu-His-Phe-Pro-Gly-Pro

The invention relates to medicine

The invention relates to a derivative of D-Proline General formula

< / BR>

< / BR>
where R is SH, benzyl or phenyl, optionally substituted by a hydroxy-group or a lower alkoxygroup, or a group of the formula

< / BR>
R1is hydrogen or halogen; X represents -(CH2)n-; -CH(R2)(CH2)n-; -CH2O(CH2)n-; CH2NH-; benzyl, -C(R2)=CH-; CH2CH (OH)- or thiazol-2,5-diyl; Y represents-S -; (CH2)n; -O-; -NH-; -N (R2)-; -CH=CH-; -NHC(O)NH-; -N(R2)C(O)N(R2)-; -N[CH2WITH6H3(OCH3)2]-; -N(CH2WITH6H5)-; -N(CH2WITH6H5)C(O)N(CH2WITH6H5)-; -N(alkoxyalkyl)-; -N(cyclooctylmethyl)-; 2,6-pyridyl; 2,5-furanyl; 2,5-thienyl; 1,2-cyclohexyl; 1,3-cyclohexyl; 1,4-cyclohexyl; 1,2-naphthyl; 1,4-naphthyl; 1,5-naphthyl; 1,6-naphthyl or diphenylene; 1,2-phenylene; 1,3-phenylene or 1,4-phenylene, where phenylenebis group optionally substituted by 1-4 substituents selected from the group comprising halogen, lower alkyl, lower alkoxygroup, the hydroxy-group, carboxypropyl, -COO-lower thiazolyl, 2-oxo[1,2,3,5] oxadiazolyl, 5-thioxo[1,2,4]oxadiazolyl and 5-tert-butylsulfonyl[1,2,4] oxadiazolyl; X' represents -(CH2)n-; (CH2)nCH(R2)-; -(CH2)nOCH2-; -NHCH2-; benzyl, -CH= C(R2)-; -CH(OH)CH2or thiazol-2,5-diyl; R2denotes lower alkyl, lower alkoxygroup or benzyl and n = 0-3, their pharmaceutically acceptable salts, mono - and diesters, except (R)-1-[(R)- and (R)-1-[(S)-3-mercapto-2-methylpropionyl] pyrrolidin-2-carboxylic acid; medicinal product with amyloidoses activity, and the method of obtaining these derivatives

The invention relates to medicine, namely to addiction, and the development of anti-craving and withdrawal syndrome in opiate addiction
The invention relates to medicine, namely to pharmacy, in particular to the drugs used for the prevention and treatment of osteoarthritis and other lesions of the joints, accompanied by degenerative changes (DDI) articulatory and tissues paraartikulyarnye

Antianginal tool // 2200026
The invention relates to medicine and can be used to treat ischemic heart disease

The invention relates to peptides-immunoregulators and their therapeutic use

The invention relates to medicine, to tuberculosis, may be used to treat various forms of tuberculosis, including drug-resistant to anti-TB chemotherapy

The invention relates to medicine and relates to a polypeptide, which is an analog of a fragment of epidermal growth factor 21 on the 31st amino acid, as vectors for targeted delivery of anticancer drugs into tumor cells
The invention relates to medicine, resuscitation and kombustiologiya, can be used for the treatment of burn disease

FIELD: medicine, cardiology.

SUBSTANCE: the suggested method should be performed at the background of medicinal therapy with preparations out of statins group, tevetene, polyoxidonium and conducting seances of plasmapheresis by removing 800 ml plasma twice weekly with N 5 due to additional intramuscular injection of immunophan 0.005%-1.0 with N 10 and fluimucyl 300 mg intravenously daily with N 5-10, total course of therapy lasts for 2 mo. The method provides modulation of leukocytic functional activity, moreover, due to altered cytokine profile and, thus, through disintegration of protein-lipid complexes participating in the development of atherosclerotic platelets.

EFFECT: higher efficiency of therapy.

3 ex

FIELD: medicine, phthisiology, anesthesiology.

SUBSTANCE: during the day of operation one should perform autohemotransfusion, then introduce epocrine intravenously by drops at the dosage of 50-200 U/kg patient's body weight; next day after interference one should inject epocrine subcutaneously at the dosage of 25-100 U/kg; at hematocrit level being below 35% 48 h after operation it is necessary to repeat subcutaneous injection of the above-mentioned preparation at the dosage not exceeding 50 U/kg. The present innovation favors hemopoiesis stimulation in postoperational period, that, in its turn, accelerates postoperational rehabilitation in patients of this group and enables, also, to avoid allotransfusions being dangerous because of immunoconflicting reactions.

EFFECT: higher efficiency of compensation.

1 ex, 1 tbl

FIELD: pharmaceutical chemistry, medicine.

SUBSTANCE: in the suggested composition one should apply heptapeptide of Met-Glu-His-Phe-Pro-Gly-Pro sequence (heptapeptide A) for treating ischemic insult due to introducing 2 drops of compositions into each nasal canal 5-6 times daily for 10 d at disease of average severity degree, and in case of severe degree - per 3 drops of the present composition into each nasal canal 7 times daily for 10 d. The present innovation provides increased efficiency at decreased concentration of heptapeptide without any side effects.

EFFECT: higher efficiency of therapy.

2 cl, 6 dwg, 8 ex, 5 tbl

FIELD: genetic engineering, medicine.

SUBSTANCE: invention relates to T-cell receptor sequence being detected in patients with extended sclerosis and is useful in diagnosis and therapy. Oligonucleotide including sequence which represents or is derived from 5'-CTAGGGCGGGCGGGACTCACCTAC-3' or nucleotide sequence being fully complementary thereto. Oligonucleotide together with nuclear acid including nearly 15-30 oligonucleotides, which doesn't comprise oligonucleotide sequence and presents in region from Vβ to Jβ of Vβ13.1 gene in T-cell Vβ13.1-subgroup, wherein oligonucleotide and nuclear acid sequences don't present in the same chain of pair sequences of Vβ13.1 gene, is used in Vβ13.1 gene part amplification. In method for detection of LGRAGLTY motive, which is present in T-cell receptors of T-cell Vβ13.1-subgroup, oligonucleotide is used in combination with labeling particle. Once LGRAGLTY motive is detected, development monitoring and treatment are carried out by removing of LGRAGLTY motive-containing peptide.

EFFECT: simplified methods for detection of LGRAGLTY motive in T-cell receptors and treatment of patients with extended sclerosis.

21 cl, 7 dwg, 3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: peptide of the following formula: X-Pro-Gly-P, where X = Thr-Lys-Pro-Arg-; Lys-pro-Arg-; pro-Arg-; Arg-, being of untiulcerous activity. They should be applied at intraperitoneal injection at the dosage of 0.58-3.20 mcM g/kg for preventing and treating ulcers of gastro-intestinal tract.

EFFECT: higher efficiency and prophylaxis.

4 dwg, 5 ex

FIELD: chemistry of peptides, medicine, oncology, pharmaceutical chemistry.

SUBSTANCE: invention relates to the development of medicinal agent of peptide nature eliciting an antitumor effect and can be used in treatment of endocrine and hormone-dependent tumors. Agent represents peptide of the general formula: . Invention provides enhancement of the therapeutic effect and reducing toxicity.

EFFECT: valuable medicinal properties of agent.

3 cl, 4 tbl, 2 ex

FIELD: medicine, surgery.

SUBSTANCE: one should introduce solution "Rheamberin 1.5%"intravenously with infusomates at the dosage of 5 ml/kg/d during the next 5 d. Then, 1-2 h later, one should infuse intravenously "Dalargin" at 30 mg/kg/d dissolved in 60 ml 0.9% sodium chloride at the rate of 120 ml/h for 5 d. Additionally, 4-5 h after "Dalargin" injection it is necessary to perform daily intravenous He-Ne laser irradiation of blood beginning since the first day at wave length being 0.63 mcm, power 1 mW, exposure 50-60 min, course lasts for 5 d. The method enables to interrupt intestinal paresis in case of vertebral traumas and wounds in earlier terms.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine, first aid, anesthesiology, resuscitation, surgery.

SUBSTANCE: along with conventional medicinal preparations applied to treat shock one should introduce crystalloids into central vein in certain sequence: 7.5% and 0.9%-sodium chloride solution, 5%-glucose solution, and, also, infucol and similar-group plasma; after stabilizing arterial pressure one should introduce, additionally, either mildronate, or dalargin at certain dosages. The present innovation enables to restore the volume of extracellular liquid in the shortest period of time at decreased volume of infusion that, in its turn, favors to remove shock and prevent other possible further complications.

EFFECT: higher efficiency.

3 ex

FIELD: bioorganic chemistry.

SUBSTANCE: invention provides somatostatin agonists of general formula: A1-cyclo{Cys-A2-D-Trp-A3-A4-Cys}-A5-Y1 (I), wherein A1 represents aromatic D- or L-α-amino acid selected from Phe, D-Phe, Tyr, D-Tyr, β-Nal, D-β-Nal, Cha, or D-Cha; A2 aromatic α-amino acid selected from Phe, Tyr, β-Nal, and Cha; A3 Lys or Orn; A4 β-hydroxyvaline, Ser, hSer, or Thr; A5 β-hydroxyvaline, Ser, hSer, or Thr; and Y1 represents NH2; amide nitrogen atoms of peptide groups and amine group of A1 in compound I are optionally substituted by methyl group, provided that at least one methyl group is available and that compound I cannot have following formula: D-Phe-cyclo{Cys-Phe-D-Trp-Lys-(N-Me-Thr)-Cys}-Thr-NH-2. pharmaceutically acceptable salts of compound I are also claimed.

EFFECT: expanded synthetic possibilities in peptide synthesis.

24 cl, 2 tbl, 18 ex

Oligopeptides // 2260597

FIELD: organic chemistry, peptides, biochemistry.

SUBSTANCE: invention describes oligopeptide or its salt taken among the group consisting of oligopeptide (1) and (2): Lys-Ser-Ile-Glu-Gln-Ser-Cys-Asp-Gln-Asp-Glu (I), Ser-Ile-Glu-Gln-Ser-Cys-Asp-Gln-Asp-Glu (II); Ser-Ile-Glu-Gln-Ser-Cys-Asp-Gln-Asp (III); Ser-Ile-Glu-Gln-Ser-Cys-Asp-Gln (IV); Ser-Ile-Glu-Gln-Ser-Cys-Asp (V); Ser-Ile-Glu-Gln-Ser-Cys (VI); Ile-Glu-Gln-Ser-Cys-Asp-Gln-Asp-Glu (VII); Glu-Gln-Ser-Cys-Asp-Gln-Asp-Glu (VIII); Gln-Ser-Cys-Asp-Gln-Asp-Glu (IX); 2) oligopeptide with amino acid sequence obtained by deleting by C- or N-end of one or some amino acids in any amino acid sequence (I)-(IX), and the modified oligopeptide representing oligopeptide biotinylated or dimerized by sulfhydryl group of cysteine residue based on oligopeptide determined in (1) or (2). Oligopeptides elicit activity with respect to hair growth stimulation.

EFFECT: valuable properties of oligopeptides.

11 cl, 6 dwg, 4 ex